Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: A preliminary study

Gabriel Lopez-Berestein, Victor Fainstein, Roy Hopfer, Kapil Mehta, Margaret P. Sullivan, Michael Keating, Michael G. Rosenblum, Reeta Mehta, Mario Luna, Evan M. Hersh, James Reuben, Rudolph L. Juliano, Gerald P. Bodey

Research output: Contribution to journalArticlepeer-review

346 Scopus citations

Abstract

Twelve patients with hematologic malignancies complicated by fungal infections were treated with liposomal amphotericin B (L-AmpB). Nine patients were granulocytopenic; the three additional patients with normal granulocyte counts were immunosuppressed. All patients had biopsy findings or cultural evidence of the progression of their fungal infection while being treated with conventional amphotericin B. Doses of 0.8-1.0 mg/kg of L-AmpB were administered intravenously every 24-72 hr. Three patients had a complete remission, five had a partial remission, and four showed no improvements. A total of 161 doses of L-AmpB were administered. Fever and chills occurred on seven occasions. No hematologic or blood chemistry abnormalities related to L-AmpB treatment were observed.

Original languageEnglish (US)
Pages (from-to)704-710
Number of pages7
JournalJournal of Infectious Diseases
Volume151
Issue number4
DOIs
StatePublished - Jan 1 1985

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: A preliminary study'. Together they form a unique fingerprint.

Cite this